NCT03261947 · MORE INFO

Limitations, agreements, and source contact

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors · Source last updated 2021-09-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: TrialDisclosures@takeda.com
organization: Takeda
phone: +1-877-825-3327
title: Study Director

Complete source fields

certain Agreement

other Details: In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: TrialDisclosures@takeda.com
organization: Takeda
phone: +1-877-825-3327
title: Study Director

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice